Lila Levinson, PhD,  Science Writer—

Cereno Scientific has received fast track designation from the U.S. Food and Drug Administration (FDA) for CS1, its therapy candidate for pulmonary arterial hypertension (PAH). “We are very pleased to have achieved Fast Track designation for CS1, which both validates the strength of our CS1 program and supports…

Most people with pulmonary arterial hypertension (PAH) are not referred for a lung transplant, despite clinical recommendations that referral should occur early in potentially eligible cases, a study reports. About 18% to 29% of participants with advanced functional class 4 disease, who guidelines recommend referrals for, received referrals.

Providing a protein called BMPER that is found at low levels in models of pulmonary arterial hypertension (PAH) may ease disease progression, a study suggests. “Our study identifies BMPER as a novel therapeutic target for pulmonary arterial hypertension and provides new insights into the underlying mechanisms of the disease,” researchers wrote.

The U.S. Food and Drug Administration (FDA) has accepted Gradient Denervation Technologies, a company that makes an ultrasound-based catheter to treat pulmonary hypertension (PH), into a program to facilitate development of medical devices. Acceptance into the FDA’s Total Product Life Cycle Advisory Program (TAP) pilot will give…

A Phase 2b clinical trial of Insmed’s treprostinil palmitil inhalation powder (TPIP) suggested daily doses of the inhaled dry powder are well tolerated and may improve blood flow and exercise capacity in adults with pulmonary arterial hypertension (PAH). “The statistically significant and clinically meaningful results shown with TPIP…

A Phase 2a study of HB-1614, an oral therapy candidate, suggested the medication is safe and may improve exercise capacity and quality of life in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). This is according to Halo Biosciences, developer of HB-1614, which announced the publication of…